Transgenic mice expressing the FTD-linked tau mutant P301L showed a decrease in cognitive deficits and reduced levels of insoluble and hyperphosphorylated tau upon administration of rolipram, a treatment that led to an increase in proteasome activity in the brain [77]. The gene discussed is MAPT; the disease is Cognitive impairment.